中国老年保健医学Issue(3)：40-41,2.DOI:10.3969/j.issn.1672-4860.2014.03.014
替吉奥胶囊联合紫杉醇脂质体治疗术后复发胃癌的疗效观察
Clinical observation of S-1 combined with paclitaxel liposome on postoperative recurrence of gastric cancer
张忠新 1宫帅 2王勐 1于春锐1
作者信息
- 1. 青岛市立医院 肿瘤二科 266011
- 2. 山东大学齐鲁医院 肿瘤科 250012
- 折叠
摘要
Abstract
Objective To explore for S-1 combined paclitaxel liposome systemic chemotherapy on postoperative recurrence of gastric cancer in the near future curative effect and adverse reactions.Methods 25 cases of gastric cancer recurrence after surgery in group,give combination paclitaxel liposome scheme for S-1 (for S-1 according to body surface area of 40~60mg,2 times/d,the first 1~14 days;paclitaxel liposome (plain,nanjing Kang Hai pharmaceutical co,LTD.) 135mg/m2,the first day drop 90 min;3 weeks ) systemic chemotherapy patients were receiving at least two cycle after the evaluation of curative effect .Results The total ef-fective rate was 48%(12/25),of which the complete response rate was 8%,partial remission rate 40%,the stability factor,clinical benefit rate of 72%.The main side effects are bone marrow suppression , peripheral nerve toxicity and gastrointestinal reac-tion.Conclusion S-1 combined paclitaxel liposome to postoperative patients with recurrent gastric cancer , the curative effect is sure,adverse reaction can be tolerated .关键词
胃癌/替吉奥(维康达) 紫杉醇脂质体/术后复发Key words
gastric cancer/S-1/paclitaxel liposome/postoperative recurrence引用本文复制引用
张忠新,宫帅,王勐,于春锐..替吉奥胶囊联合紫杉醇脂质体治疗术后复发胃癌的疗效观察[J].中国老年保健医学,2014,(3):40-41,2.
